



International Journal of Current Innovations in Advanced Research

(International Multidisciplinary Tri-annual Research Journal)

Content Available at www.ijciar.com ISSN (O) 2636-6282 ISSN (P) 2659-1553



DEVELOPMENT AND VALIDATION OF NEW RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF DELAMANID AND BEDAQUILINE IN COMBINED PHARMACEUTICAL DOSAGE FORMS

NAGARAJUPAPPULA^{1*}, NETHULURI SRINIVAS¹, V. VASU NAIK²,
G. INDIRA PRIYADARSHINI¹, V. MOUNIKA¹, ANDUPENDRA RAO UTTARAVELLI³

¹Department of Pharmaceutical Analysis, Hindu College of Pharmacy, Guntur – 522002, A.P., India

²Department of Pharmaceutics, Hindu College of Pharmacy, Guntur – 522002, A.P., India

³Sri Sivani College of Pharmacy, Chilakapalem, Srikakulam, A.P., India

*CORRESPONDING AUTHOR

Nagaraju Pappula

Received: 19 Mar 2026 Revised: 09 May 2026 Accepted: 03 Aug 2026

ABSTRACT

A simple, accurate, precise, and economical RP-HPLC method was developed and validated for the simultaneous estimation of Delamanid and Bedaquiline in bulk drug and pharmaceutical dosage forms. Chromatographic separation was achieved using a Kromasil C18 column (150 × 4.6 mm, 5.0 μm) with a mobile phase consisting of 0.1N Potassium Dihydrogen orthophosphate and acetonitrile in the ratio of 60:40 % v/v. The mobile phase was pumped at a flow rate of 1.0 mL/min, and the column temperature was maintained at 30°C. The ammonium acetate buffer was prepared by adding 0.1% acetic acid and adjusting the pH to 3.8. The optimized detection wavelength was 220 nm. The retention times of Delamanid and Bedaquiline were found to be 2.249 and 2.970 min, respectively. The percentage RSD for Delamanid and Bedaquiline was found to be 1.4% and 0.5%, respectively, indicating good precision. The percentage recovery was found to be 99.69% for Delamanid and 99.90% for Bedaquiline. The LOD and LOQ values obtained from the regression equations were 0.10 and 0.29 for Delamanid and 0.25 and 0.74 for Bedaquiline, respectively. The assay results were found to be 99.52% for Delamanid and 99.95% for Bedaquiline. The regression equations were $y = 19629x + 3362.1$ for Delamanid and $y = 23316x + 9810.4$ for Bedaquiline. The developed method provided short retention times and reduced total analysis time, making it simple, rapid, economical, and suitable for routine quality control analysis of Delamanid and Bedaquiline in pharmaceutical industries.

Keywords: Delamanid, Bedaquiline, RP-HPLC, Simultaneous Estimation, Method Validation, Pharmaceutical Dosage Form.

©2026The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



1. INTRODUCTION

Bedaquiline (Fig. 01) is indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary tuberculosis (TB) due to *Mycobacterium tuberculosis* resistant to at least rifampin and isoniazid. Bedaquiline is primarily subjected to oxidative metabolism leading to the formation of N-monodesmethyl metabolite (M2). M2 is not thought to contribute significantly to clinical efficacy given its lower average exposure (23% to 31%) in humans and lower antimycobacterial activity (4-fold to 6-fold lower) than the parent compound. However, M2 plasma concentrations appeared to correlate with QT prolongation. Bedaquiline is a diarylquinoline antimycobacterial drug that inhibits mycobacterial ATP (adenosine 5'-triphosphate) synthase, by binding to subunit c of the enzyme that is essential for the generation of energy in *M. tuberculosis* [1]. Delamanid (Fig. 02) is an antibiotic used to treat multidrug resistant tuberculosis. It is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. The minimum inhibitory concentrations (MIC) of delamanid against *Mycobacterium tuberculosis* isolates ranges from 0.006 to 0.024 g/mL. Among non-tuberculosis mycobacteria, delamanid has *in vitro* activity against *M.*

kansasii and *M. bovis*. Delamanid has no in vitro activity against Gram negative or positive bacterial species and does not display cross-resistance to other anti-tuberculosis drugs. Delamanid is a prodrug that requires biotransformation via the mycobacterial F420 coenzyme system, including the deazaflavin dependent nitroreductase (Rv3547), to mediate its antimycobacterial activity against both growing and nongrowing mycobacteria. Mutations in one of five coenzyme F420 genes, *fgd*, *Rv3547*, *fbiA*, *fbiB*, and *fbiC* has been proposed as the mechanism of resistance to delamanid [2].




Figure 01: Molecular Structure of Bedaquiline




Figure 02: Molecular Structure of Delamanid

Detailed survey of literature revealed that analytical methods are reported by using Liquid Chromatography [3-6], for the estimation of Bedaquiline and Delamanid alone as well as in combination with other drugs using pharmaceutical formulations. The present research work is aimed to develop a simple, rapid, accurate, sensitive and stability indicating method for simultaneous estimation of the above mentioned two drugs for routine analysis with shorter run time. The proposed method is optimized and validated as per the International Conference on Harmonization (ICH) guidelines [7].

2. MATERIALS AND METHODS

2.1. Materials

Bedaquiline and delamanid reference standards and their combined pharmaceutical dosage form were used for the study. HPLC-grade acetonitrile, methanol, potassium dihydrogen orthophosphate, orthophosphoric acid, and distilled/milli-Q water were procured from Rankem, India. Hydrogen peroxide, hydrochloric acid, and sodium hydroxide were used for forced-degradation studies.

2.2. Instruments

The analysis was performed using a Waters HPLC 2695 system equipped with a quaternary pump, autosampler, and photodiode-array (PDA) detector, operated using Empower 2 software. A PG Instruments T60 UV-visible spectrophotometer with matched quartz cells was used for spectrophotometric measurements. A Denver electronic balance, pH meter, and ultrasonicator (BVK Enterprises, India) were also used.

2.3. Preparation of Solutions

Acetonitrile:water (50:50, v/v) was selected as the diluent based on the solubility of the drugs. Standard stock solutions were prepared separately by accurately weighing 10 mg of delamanid and 20 mg of bedaquiline into 50-mL volumetric flasks, dissolving with diluent using sonication, and making up to volume to obtain concentrations of 200 and 400 µg/mL, respectively. Working standard solutions were prepared by appropriate dilution to obtain final concentrations of 20 µg/mL delamanid and 40 µg/mL bedaquiline.

For sample preparation, ten tablets were weighed and powdered, and an amount equivalent to one tablet was transferred to a volumetric flask. Acetonitrile was added and the mixture was sonicated, followed by dilution with the selected diluent. The solution was filtered through a 0.45-µm membrane filter and further diluted to obtain concentrations equivalent to 20 µg/mL of delamanid and 40 µg/mL of bedaquiline.

2.4. Preparation of Buffer

A 0.1 N potassium dihydrogen orthophosphate buffer was prepared by dissolving 1.36 g of potassium dihydrogen orthophosphate in approximately 900 mL of milli-Q water. The solution was sonicated and degassed, diluted to 1000 mL with water, and treated with 1 mL of triethylamine. The pH was adjusted to 3.8 using dilute orthophosphoric acid.

2.5. Method Validation

The developed HPLC method was validated in accordance with applicable ICH guidelines for system suitability, specificity, precision, linearity, accuracy, robustness, limit of detection (LOD), limit of quantification (LOQ), and stability-indicating capability.

System Suitability

Standard solutions containing 20 µg/mL delamanid and 40 µg/mL bedaquiline were injected six times. Retention time, peak area, theoretical plate count, peak tailing, and resolution were evaluated. The percentage relative standard deviation (%RSD) of peak areas was required to be not more than 2%.

Specificity

Specificity was assessed by injecting blank, standard, and sample solutions. The chromatograms were examined for any interfering peaks at the retention times of delamanid and bedaquiline.

Precision

Method precision was evaluated by analyzing the standard solution containing 20 µg/mL delamanid and 40 µg/mL bedaquiline. The precision was expressed as %RSD of the assay results.

Linearity

Linearity was evaluated using standard solutions corresponding to 25–150% of the working concentration. The concentrations used were 5–30 µg/mL for delamanid and 10–60 µg/mL for bedaquiline. Calibration curves were constructed by plotting peak area against concentration, and the regression equation and correlation coefficient were determined.

Accuracy

Accuracy was assessed by the standard-addition method at 50%, 100%, and 150% levels. Known quantities of delamanid and bedaquiline standards were spiked into the sample solution and analyzed. Percentage recovery was calculated, with an acceptance range of 98.0–102.0%.

Robustness

Robustness was evaluated by introducing deliberate variations in chromatographic conditions, including flow rate, mobile-phase composition, and column temperature. Flow rates of 0.9 and 1.1 mL/min and temperatures of 25 and 35°C were evaluated. The effect of these changes on system suitability and assay results was assessed.

LOD and LOQ

LOD and LOQ were evaluated by serial dilution of standard solutions to obtain low-concentration solutions of delamanid and bedaquiline. The corresponding chromatographic responses (Fig. 03 & 04) were evaluated to establish the detection and quantification limits of the method.




Figure 03: LOD Chromatogram




Figure 04: LOQ Chromatogram

Forced-Degradation Studies

Forced-degradation studies were performed to establish the stability-indicating capability of the developed method. Standard drug solutions were subjected to acid, alkali, oxidative, thermal, photolytic, and neutral degradation conditions.

For **oxidative degradation**, standard solutions were treated with 20% hydrogen peroxide and maintained at 60°C for 30 min.

For **acid degradation**, the drug solutions were treated with 2 N hydrochloric acid and refluxed at 60°C for 30 min.

For **alkali degradation**, the drug solutions were treated with 2 N sodium hydroxide and refluxed at 60°C for 30 min.

For **thermal degradation**, the drug solutions were exposed to dry heat at 105°C for 1 h.

For **photolytic degradation**, the drug solutions were exposed to UV radiation in a photostability chamber for 1 day (approximately 200 Wh/m²).

For **neutral degradation**, the drug solutions were refluxed in water at 60°C for 1 h.

Following stress treatment, the solutions were appropriately diluted to obtain concentrations of 20 µg/mL delamanid and 40 µg/mL bedaquiline. A 10-µL aliquot was injected into the HPLC system, and the chromatograms were evaluated for degradation and the presence of additional peaks. The developed method was considered stability-indicating based on its ability to resolve the drug peaks from their degradation products.

3. RESULTS AND DISCUSSION

3.1 Selection of Detection Wavelength

The UV spectra of delamanid and bedaquiline were evaluated to identify a suitable wavelength for simultaneous detection. Based on the spectral response of both drugs, **220 nm** was selected as the optimized detection wavelength for the chromatographic analysis.

3.2 Method Development and Optimization

The chromatographic method was developed by systematically varying the mobile-phase composition, organic modifier, stationary phase, and chromatographic conditions. Several trials were performed to obtain satisfactory peak shape, resolution, retention time, and system suitability table 01.

In the first trial, methanol:0.1% orthophosphoric acid (50:50, v/v) was used as the mobile phase with an Ascantis C18 column. Both drugs were eluted; however, peak fronting was observed. In the second trial, acetonitrile:0.1% orthophosphoric acid (50:50, v/v) was used with the same column. Although both compounds were eluted within a short runtime, splitting of the bedaquiline peak was observed. In the third trial, the column was changed to a Discovery C18 column; however, broad peaks and peak splitting persisted. In the fourth trial, a Kromasil C18 column was employed with acetonitrile:0.1% orthophosphoric acid (50:50, v/v). Both drugs were eluted, but asymmetry of the bedaquiline peak was observed.

Based on these observations, the chromatographic conditions were further optimized using a **Kromasil C18 column (4.6 × 150 mm, 5 µm)** with **0.01 N potassium dihydrogen phosphate buffer:acetonitrile (60:40, v/v)** as the mobile phase. The flow rate was maintained at 1.0 mL/min, the column temperature at 30°C, detection wavelength at 220 nm, injection volume at 10 µL, and total runtime at 6 min. Acetonitrile:water (50:50, v/v) was used as the diluent.

Under the optimized conditions, delamanid and bedaquiline were eluted (fig. 05) at approximately **2.24 and 2.97 min**, respectively, with satisfactory peak symmetry, theoretical plate count, and resolution. The method therefore provided rapid and efficient simultaneous separation of both drugs and was selected for further validation. Optimized Chromatographic Conditions were shown in Table 01.

Table 01: Optimized RP-HPLC chromatographic conditions for simultaneous estimation of Delamanid and Bedaquiline

Parameter	Optimized condition
Column	Kromasil C18, 4.6 × 150 mm, 5 µm
Mobile phase	0.01 N KH ₂ PO ₄ buffer:acetonitrile (60:40, v/v)
Flow rate	1.0 mL/min
Detection wavelength	220 nm
Column temperature	30°C
Injection volume	10 µL

Runtime	6 min
Diluent	Acetonitrile:water (50:50, v/v)
Delamanid retention time	~2.24 min
Bedaquiline retention time	~2.97 min




Figure 05: Optimized Chromatogram

3.3 System Suitability

System suitability was evaluated by six replicate injections of the standard solution containing 20 µg/mL delamanid and 40 µg/mL bedaquiline. The retention times, theoretical plate counts, tailing factors, and resolution were satisfactory. The mean retention times were approximately 2.25 min for delamanid and 2.98 min for bedaquiline. The theoretical plate counts were greater than 6800 for delamanid and 12,000 for bedaquiline, while the tailing factors were below 1.5. Resolution between the two peaks was approximately 6.3–6.4. The %RSD of peak areas was within the prescribed limit of 2.0%, confirming the suitability of the chromatographic system (fig. 06).




Figure 06: System suitability Chromatogram

3.4 Specificity

Specificity was established by comparing chromatograms of the blank, placebo, standard, and sample solutions. No significant interfering peaks were observed at the retention times of delamanid and bedaquiline. The method was therefore considered specific for the simultaneous determination of both drugs in the pharmaceutical formulation.

3.5 Linearity

The linearity of the method was evaluated over the concentration ranges of **5–30 µg/mL for delamanid** and **10–60 µg/mL for bedaquiline**. The calibration curves showed a strong linear relationship between concentration and peak area.

For delamanid, the regression equation was:

$$y = 19629x + 3362.1$$

For bedaquiline, the regression equation was:

$$y = 23316x + 9810.4$$

The correlation coefficient was **0.999 for both drugs**, demonstrating excellent linearity within the investigated concentration ranges.

3.6 Precision

System Precision

System precision was evaluated using six replicate injections of the standard solution. The %RSD of peak areas was **1.5% for delamanid** and **0.4% for bedaquiline**, which were below the acceptance criterion of 2.0%. The results confirmed satisfactory instrument precision.

Method Precision

Repeatability was assessed by analyzing six independently prepared sample solutions. The %RSD values were **0.3% for delamanid** and **0.2% for bedaquiline**, indicating good repeatability of the analytical method.

Intermediate Precision

Intermediate precision was assessed on a different day using the same analytical procedure. The %RSD values were **0.3% for delamanid** and **0.2% for bedaquiline**. These results demonstrated good reproducibility of the method under different analytical conditions.

3.7 Accuracy

Accuracy was determined by the standard-addition method at 50%, 100%, and 150% concentration levels. Triplicate determinations were performed at each level. The mean percentage recoveries were **99.69% for delamanid** and **99.90% for bedaquiline**, demonstrating satisfactory accuracy of the method and compliance with the acceptance range of 98–102%.

3.8 Sensitivity

The sensitivity of the developed method was determined in terms of the limit of detection (LOD) and limit of quantification (LOQ). The LOD values were **0.10 µg/mL for delamanid** and **0.25 µg/mL for bedaquiline**, while the corresponding LOQ values were **0.29 µg/mL** and **0.74 µg/mL**, respectively. These results indicate that the method is sufficiently sensitive for the determination of both drugs at low concentrations.

3.9 Robustness

Robustness was evaluated by introducing deliberate variations in flow rate, mobile-phase composition, and column temperature. The flow rate was varied to 0.9 and 1.1 mL/min, while changes in mobile-phase composition and temperature were also evaluated.

The %RSD values obtained under the different conditions ranged from **0.1–0.9% for delamanid** and **0.1–0.7% for bedaquiline**, all of which were below the acceptance criterion of 2.0%. No significant changes in chromatographic performance were observed. The method was therefore considered robust.

3.10 Assay of Pharmaceutical Formulation

The validated method was applied to the simultaneous assay of delamanid and bedaquiline in the combined pharmaceutical formulation containing **20 mg of delamanid and 40 mg of bedaquiline** per dosage unit.

The mean assay values were **99.52% for delamanid** and **99.95% for bedaquiline**, with %RSD values of **0.3% and 0.2%**, respectively. The results were within the acceptable assay limits, demonstrating the applicability of the developed method for routine quality control analysis of the formulation.

3.11 Forced-Degradation Studies

Forced-degradation studies were performed on the pharmaceutical formulation under acidic, alkaline, oxidative, thermal, photolytic, and neutral conditions. The stressed samples were analyzed using the developed HPLC method to evaluate drug degradation and demonstrate its stability-indicating capability.

Delamanid showed degradation of **6.16% under acidic**, **4.54% under alkaline**, **4.02% under oxidative**, **2.54% under thermal**, **2.06% under photolytic**, and **1.17% under neutral** conditions. The corresponding undegraded drug contents were 93.84%, 95.46%, 95.98%, 97.46%, 97.94%, and 98.83%, respectively table 02.

Bedaquiline showed degradation of **5.45% under acidic**, **4.11% under alkaline**, **3.68% under oxidative**, **2.99% under thermal**, **1.98% under photolytic**, and **0.95% under neutral** conditions. The corresponding undegraded drug contents were 94.55%, 95.89%, 96.32%, 97.01%, 98.02%, and 99.05%, respectively.

Among the stress conditions investigated, both drugs showed comparatively greater degradation under acidic conditions, followed by alkaline and oxidative conditions. The chromatograms demonstrated separation of the drug peaks from degradation products, confirming the stability-indicating capability of the developed method. Forced-Degradation Results were shown in Table 02. Summary of Validation Results were shown in Table 03.

Table 02: Results of forced degradation studies of Delamanid and Bedaquiline under different stress conditions

Stress condition	Delamanid degraded (%)	Delamanid undegraded (%)	Bedaquiline degraded (%)	Bedaquiline undegraded (%)
Acid	6.16	93.84	5.45	94.55
Alkali	4.54	95.46	4.11	95.89
Oxidation	4.02	95.98	3.68	96.32
Thermal	2.54	97.46	2.99	97.01
UV	2.06	97.94	1.98	98.02
Water	1.17	98.83	0.95	99.05

Table 03: Validation parameters and results for the simultaneous estimation of Delamanid and Bedaquiline

Validation parameter	Delamanid	Bedaquiline	Acceptance criterion
Linearity range (µg/mL)	5–30	10–60	—
Correlation coefficient	0.999	0.999	Close to 1.0
Regression equation	$y = 19629x + 3362.1$	$y = 23316x + 9810.4$	—
Mean assay (%)	99.52	99.95	90–110%
Specificity	Specific	Specific	No interference
System precision (%RSD)	1.5	0.4	NMT 2.0%
Method precision (%RSD)	0.3	0.2	NMT 2.0%
Accuracy (% recovery)	99.69	99.90	98–102%
LOD (µg/mL)	0.10	0.25	—
LOQ (µg/mL)	0.29	0.74	—
Robustness (%RSD range)	0.1–0.9	0.1–0.7	NMT 2.0%

The developed RP-HPLC method provided rapid and efficient simultaneous separation of delamanid and bedaquiline using a Kromasil C18 column and a 0.01 N potassium dihydrogen phosphate buffer:acetonitrile mobile phase (60:40, v/v) table 03. The short retention times and satisfactory resolution enabled rapid analysis within a 6-min runtime.

The method demonstrated satisfactory specificity, linearity, precision, accuracy, sensitivity, and robustness. The low %RSD values obtained during precision and robustness studies confirmed the reliability and reproducibility of the method. The assay results were close to the labeled claim, indicating its suitability for quantitative analysis of the combined pharmaceutical formulation. Forced-degradation studies demonstrated measurable degradation under different stress conditions while maintaining adequate separation of the drug peaks from degradation products, confirming the stability-indicating nature of the method.

A rapid, accurate, precise, sensitive, specific, robust, and stability-indicating RP-HPLC method was successfully developed and validated for the simultaneous estimation of delamanid and bedaquiline in bulk and pharmaceutical dosage form. The method showed excellent linearity, satisfactory recovery, low variability, and adequate sensitivity. The developed method can therefore be applied for routine quality-control analysis and stability assessment of delamanid and bedaquiline-containing pharmaceutical formulations.

4. CONCLUSION

A simple, rapid, accurate, precise, and robust RP-HPLC method was developed and validated for the simultaneous estimation of delamanid and bedaquiline in bulk drug and pharmaceutical dosage form. The retention times of delamanid and bedaquiline were 2.249 and 2.970 min, respectively. The method showed good precision, with %RSD values of 1.4% for delamanid and 0.5% for bedaquiline. The mean percentage recoveries were 99.69% and 99.90% for delamanid and bedaquiline, respectively, confirming the accuracy of the method. The LOD and LOQ values were 0.10 and 0.29 µg/mL for delamanid and 0.25 and 0.74 µg/mL for bedaquiline, respectively. The assay results were 99.52% for delamanid and 99.95% for bedaquiline. The calibration curves exhibited good linearity, with regression equations of $y = 19629x + 3362.1$ for delamanid

and $y = 23316x + 9810.4$ for bedaquiline. The short retention times and 6-min total run time demonstrate that the proposed method is rapid, economical, and suitable for routine quality-control analysis of delamanid and bedaquiline in pharmaceutical formulations.

FUNDING

Nil

CONFLICT OF INTEREST

Not declared

INFORMED CONSENT AND ETHICAL STATEMENT

Not Applicable

AUTHOR CONTRIBUTIONS

All Authors Are Contributed Equally

REFERENCES

1. <https://go.drugbank.com/drugs/DB08903>
2. <https://go.drugbank.com/drugs/DB11637>
3. Tejaswini Bharat More, Hemlata Sanjay Bhavar., "Development and validation of RP-HPLC method for Estimation of Delamanid in pharmaceutical dosage, International Journal Of Novel Research And Development, ISSN:2456-4184, Vol.10, Issue 1, page no.d14-d20, January-2025.
4. J Chandrudu and Gandhimathi R (2024), Method Development and Validation for Estimation of Bedaquiline and in Tablet Dosage form by Hptlc and Rp-Hplc Study. Biomed Pharmacol J 2024;17(1).
5. Advaita B. Patel et al., Stability Indicating HPLC Method for the Determination of Delamanid in Pharmaceutical Dosage Form, Journal of Drug Delivery and Therapeutics 11(1-s):108-112, 2021.
6. S. J. S. Flora et al., RP-HPLC method development and validation for bedaquiline fumarate to evaluate its forced degradation behaviour and stability in official dissolution media, Future Journal of Pharmaceutical Sciences, 6(42), 2020.
7. Guideline ICH. Validation of analytical procedures: text and methodology. Q2 (R1). 2005 Nov;1.